Japan's MBL Licenses RIP-Chip to Envoy Therapeutics for Use in Drug Discovery Programs

Under the terms of the agreement, Jupiter, Fla.-based Envoy will use MBL's platform to discover biomarkers related to schizophrenia, Parkinson’s disease, Alzheimer’s disease, drug addiction, and epilepsy.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.